⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008534 | 0.79 | — | — | |
| SCHEMBL6005042 | 0.75 | — | — | |
| SCHEMBL22229856 | 0.74 | — | — | |
| SCHEMBL6005320 | 0.74 | OPRM1 (0.44) | — | |
| SCHEMBL269617 | 0.71 | — | — | |
| SCHEMBL25179 | 0.69 | — | — | |
| SCHEMBL847435 | 0.67 | — | — | |
| SCHEMBL3674350 | 0.67 | — | — | |
| SCHEMBL17333311 | 0.67 | — | — | |
| SCHEMBL513909 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| CN-105916499-B | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2020-02-18 | — | — | CN | disclosed |
| US-20190084928-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING AROMATIC AMIDE, METHOD FOR PRODUCING PYRROLE-IMIDAZOLE POLYAMIDE, AND COMPOUND | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) | 2019-03-21 | — | — | US | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| EP-3096751-A1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics AG (AT) | 2016-11-30 | — | — | EP | disclosed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | disclosed |
| WO-2015110481-A1 | 12-EPI-PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2015-07-30 | — | — | WO | disclosed |
| EP-2375899-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | Array Biopharma, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010080864-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-5922741-A | 5-aminopyrazoles useful as tyrosine kinase inhibitors | CELLTECH THERAPEUTICS LTD. (GB) | 1999-07-13 | — | — | US | disclosed |
| EP-0906286-A1 | 5-AMINOPYRAZOLES USEFUL AS SELECTIVE INHIBITORS OF THE PROTEIN TYROSINE KINASE P56ICK | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997040019-A1 | 5-AMINOPYRAZOLES USEFUL AS SELECTIVE INHIBITORS OF THE PROTEIN TYROSINE KINASE P56ICK | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-10-30 | — | — | WO | disclosed |